AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences.
| Event: | Morgan Stanley - 21stAnnual Global Healthcare Conference |
| Format: | Fireside chat with Remi Barbier, President & CEO |
| Date: | Monday, September 11, 2023 |
| Where: | New York City |
| Event: | H.C. Wainwright - 25thAnnual Global Investment Conference |
| Format: | Corporate presentation by Eric Schoen, Chief Financial Officer |
| Date: | Monday, September 11, 2023 |
| Where: | New York City |
| Event: | JonesTrading - 2023 Healthcare Summit |
| Format: | Fireside chat with Remi Barbier, President & CEO |
| Date: | Tuesday, October 10th, 2023 |
| Where: | Miami |
| Event: | Jefferies - Inaugural Biotech CNS/Neuro Summit |
| Format: | Fireside chat with management |
| Date: | Wednesday, October 11, 2023 |
| Where: | New York City |
A webcast or subsequent archived replay of Cassava Sciences’ participation in these events may be available, depending on the conference and other factors. If a webcast or replay becomes available, it may be accessed via the Investors section of Cassava Sciences’ website at: www.CassavaSciences.com.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.39 |
| Daily Change: | -0.05 -3.15 |
| Daily Volume: | 224,749 |
| Market Cap: | US$66.630M |
March 25, 2025 February 27, 2025 November 25, 2024 November 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
